News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>CMBI: CSPC PHARMA Out-licensing Deals Could Be Sustainable Revenue Growth Engine; Rating Buy Kept
CMBI published a research report covering CSPC PHARMA (01093.HK), which logged a 10.4% YoY decline in total revenue to RMB26 billion in 2025, under impact of volume-based procureme...
Reset
Send
The window will close in 5 seconds
<Research>CMBI: CSPC PHARMA Out-licensing Deals Could Be Sustainable Revenue Growth Engine; Rating Buy Kept
Close
Recommend
6
Positive
9
Negative
6
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

CMBI published a research report covering CSPC PHARMA (01093.HK)  +0.090 (+0.936%)    Short selling $314.42M; Ratio 92.374%   , which logged a 10.4% YoY decline in total revenue to RMB26 billion in 2025, under impact of volume-based procurement (VBP) and prescription controls. However, core domestic sales are bottoming out and are expected to stabilize in 2026.

Meanwhile, the company has transformed into a global innovative pharmaceutical enterprise, continuously achieving out-licensing deals, which could become a sustainable revenue growth engine. On the back of a differentiated pipeline, the broker expected recurring business development income to juice long-term growth.

CMBI forecast CSPC's net profits for 2026-28 to be RMB5.706 billion/ RMB5.62 billion/ RMB6.97 billion, respectively, compared to RMB3.876 billion in 2025.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)



This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.